Clinical Trials
Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials
Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc have entered into a multi-year strategic alliance to develop innovative models for clinical trials. Through this partnership, Pfizer and Ochsner — through its innovation...
Clinical Trials
CStone receives CTA approval in China to start Phase I trial for FGFR4 inhibitor BLU-554
CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) recently approved the clinical trial application (CTA) to start a Phase I clinical trial in China for BLU-554 (CS3008). An inhibitor of fibroblast growth factor receptor...
Clinical Trials
Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial
Bavarian Nordic A/S announced , that the first stage of a Phase 2 study of its novel, targeted cancer immunotherapy candidate, BN-Brachyury in the treatment of advanced chordoma has completed recruitment of the planned 10 patients ahead of schedule....
Clinical Trials
Phase 3 Trial of Rova T as Second-line Therapy for Advanced Small-Cell Lung Cancer Halted
AbbVie , a research-based global biopharmaceutical company, announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung cancer (SCLC). An...
Articles
The importance of biometric functions to improving data quality in Clinical Trials
Reducing the costs associated with clinical trials is one of the pharmaceutical industry’s core challenges. Running a clinical trial is incredibly expensive and if a compound fails in the late phases, it can be catastrophic for its sponsor company.
One...
Articles
How implementing electronic clinical outcome assessments (eCOA) into Oncology Clinical Trials Reduces the Burden of Data Collection
Clinical oncology research is unique when compared to other therapeutic areas. Cancer patients experience substantial physical and psychosocial consequences of the disease and its treatment and much of the symptom burden occurs outside the clinical environment.
Oncology research is uniquely...
Clinical Trials
AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV
AstraZeneca and MedImmune, its global biologics research and development arm, announced final overall survival (OS) results for the Phase III MYSTIC trial. A randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
